Abstract
Statement of the study: Clotiapine is a neuroleptic with chemical structure
similar to clozapine. It is often said that patients unresponsive to other neuroleptics respond to clotiapine. However, after the discovery of D-2 blockade as a
mechanism of neuroleptic efficacy, this claim seemed to lack logical theoretical
basis. The success of clozapine in patients unresponsive to other dopamine
blockers raised hopes for the discovery of new antipsychotic drugs with new
mechanisms of action. Several clozapine-like compounds have been introduced
or are in the process of being introduced, although the biochemical basis of
clozapine’s unique properties is still unknown.
Methods: We are conducting a study of severe chronic active psychotic
hospitalized patients with a history of nonresponse to at least 3 neuroleptics. The design is double-blind crossover of clotiapine as monotherapy vs. chlorpromazine as monotherapy. No washout is necessary from previous neuroleptic treatment, and flexible overlap over 2 weeks with the study medication is individualized for each patient. Patients are treated for 3 months with clotiapine and 3 months with chlorpromazine, in random order. Medication is supplied in identical capsules of 100 mg chlorpromazine or 50 mg of clotiapine. BPRS and Nurse’s Observation Scale (NOSIE) are rated every 2 weeks.
Summary of results: Data analysis on the first 32 patients will be presented.
Conclusion: Some classic “typical” antipsychotic compounds should be reevaluated for “atypical” properties.
similar to clozapine. It is often said that patients unresponsive to other neuroleptics respond to clotiapine. However, after the discovery of D-2 blockade as a
mechanism of neuroleptic efficacy, this claim seemed to lack logical theoretical
basis. The success of clozapine in patients unresponsive to other dopamine
blockers raised hopes for the discovery of new antipsychotic drugs with new
mechanisms of action. Several clozapine-like compounds have been introduced
or are in the process of being introduced, although the biochemical basis of
clozapine’s unique properties is still unknown.
Methods: We are conducting a study of severe chronic active psychotic
hospitalized patients with a history of nonresponse to at least 3 neuroleptics. The design is double-blind crossover of clotiapine as monotherapy vs. chlorpromazine as monotherapy. No washout is necessary from previous neuroleptic treatment, and flexible overlap over 2 weeks with the study medication is individualized for each patient. Patients are treated for 3 months with clotiapine and 3 months with chlorpromazine, in random order. Medication is supplied in identical capsules of 100 mg chlorpromazine or 50 mg of clotiapine. BPRS and Nurse’s Observation Scale (NOSIE) are rated every 2 weeks.
Summary of results: Data analysis on the first 32 patients will be presented.
Conclusion: Some classic “typical” antipsychotic compounds should be reevaluated for “atypical” properties.
| Original language | English GB |
|---|---|
| Pages (from-to) | S411-S411 |
| Journal | International Journal of Neuropsychopharmacology |
| Volume | 7 |
| Issue number | 2 |
| DOIs | |
| State | Published - Jun 2004 |